ARDX Ardelyx, Inc.
$3.10▲ +3.33%
Healthcare
Other
Volume 3.94M
Avg Volume (10D) 4.33M
Key Metrics & Fundamentals
Market Cap
$800.38M
P/E Ratio
–
Div Yield
0.00%
52W Range
2.96 - 8.40
% vs 50 MA
-10.48%
% vs 200 MA
-42.31%
RSI-14
40.4
MACD Histogram
+0.0100
Beta (1Y vs SPY)
0.82
Free Cash Flow
-$6.41M
Gross Rev
$120.88M
Gross Profit
$115.12M
EBITDA
-$9.78M
COGS
$5.76M
Operating Exp
$127.54M
Operating Income
-$12.43M
EBIT
-$12.43M
Pretax Income
-$16.61M
Net Income
-$16.72M
EPS (Diluted)
-0.07
Price & Volume History
Loading chart…
Recent News
Ardelyx Presents Real-World Data at ASN Kidney Week 2026 Showing Serum Phosphate Reductions Following XPHOZAH® (tenapanor) Initiation With or Without Phosphate Binders
GlobeNewswire · Oct 23, 2026 4:01 PM ET
Ardelyx to Report Third Quarter 2026 Financial Results on November 3, 2026
GlobeNewswire · Oct 20, 2026 7:30 AM ET
Wedbush Cuts Price Target on Ardelyx to $8 From $9, Keeps Outperform Rating
MT Newswires · Oct 19, 2026 7:09 AM ET
Ardelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA® Initiation in Adults with IBS-C
GlobeNewswire · Oct 12, 2026 8:01 AM ET
New Strong Sell Stocks for October 9th
Zacks · Oct 9, 2026 5:12 AM ET
New Strong Sell Stocks for October 7th
Zacks · Oct 7, 2026 2:23 AM ET
Ardelyx to Present New Data on Hyperphosphatemia Management at ASN Kidney Week 2026
GlobeNewswire · Oct 5, 2026 8:01 AM ET
Ardelyx Earns Multiple Honors at the 2026 PM360 Trailblazer Awards
GlobeNewswire · Sep 30, 2026 8:01 AM ET
Ardelyx Targets $500M Revenue This Year, Profitability by 2027
MarketBeat · Sep 21, 2026 4:02 AM ET
Hyperphosphatemia Market Insight, Epidemiology, and Market Forecast to 2036 Now Available — See Which Novel Mechanism Could Unseat Sevelamer as Phosphate Binders Face a Pill-Burden Reckoning
GlobeNewswire · Sep 8, 2026 10:45 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See ARDX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.